Plasmapp (405000) announced on the 12th that it signed a supply contract worth approximately 1.1 billion won with QMED of the United States on the 10th.

Plasmap signed a mid- to long-term supply contract worth KRW 89.5 billion with QMED in November of this year, and is in the process of shipping in December, receiving orders for about 17% of the previous year's sales (approximately KRW 1.1 billion) just one month after signing the contract. A company official said, “Orders and shipments are being placed after a number of large-scale contracts, and this year’s sales have already more than doubled compared to last year.”

A contract has been signed with QMED for the dental and veterinary hospital markets in the United States, and full-fledged regional market expansion is underway for medical low-temperature plasma sterilizer (STERLINK) and implant regenerative activator (ACTILINK) products sold in the global market. QMED is conducting marketing to expand into new markets across the U.S. orthopedics, ophthalmology, and medical industries, and Plasmap is also reviewing supply contracts to expand into new markets, and is expected to more than double its sales next year. there is.

Youbong Lim, CEO of Plasmapp, said, “We are pursuing two-dimensional growth in earnest through regional expansion and application market expansion, and we are also focusing on long-term growth by continuously developing products that can immediately respond to the rapidly changing market using our innovative plasma technology. “With the growth of Plasmapp, we will do our best at every moment to turn a profit by 2023 and grow into a global healthcare unicorn company through sound management,” he said.

Source: Edaily ( https://www.edaily.co.kr/ )